192 related articles for article (PubMed ID: 9516602)
1. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
[TBL] [Abstract][Full Text] [Related]
2. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
[TBL] [Abstract][Full Text] [Related]
4. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
6. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel plus epirubicin in advanced breast cancer.
Conte PF; Gennari A; Salvadori B; Pazzagli C; Bengala C
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):40-4. PubMed ID: 9516603
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Bishop JF; Dewar J; Toner GC; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):19-23. PubMed ID: 9144686
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Yeo W; Mok TS; Tse KK; Kwan WH; Lam KC; Ho WM; Chiu SK; Chan AT; Leung TW; Mo FK; Johnson PJ
Anticancer Drugs; 2002 Jul; 13(6):655-62. PubMed ID: 12172512
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
Gianni L
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
[TBL] [Abstract][Full Text] [Related]
20. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]